1BD Stock Overview
A biotechnology company, engages in the research, development, manufacture, and supply of agarose-based separation products to purify proteins, enzymes, antibodies, peptides, and other biomolecules primarily in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Bio-Works Technologies AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.10 |
| 52 Week High | SEK 0.25 |
| 52 Week Low | SEK 0.044 |
| Beta | 1.18 |
| 1 Month Change | 10.38% |
| 3 Month Change | 42.05% |
| 1 Year Change | -48.72% |
| 3 Year Change | -92.90% |
| 5 Year Change | n/a |
| Change since IPO | -89.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1BD | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 3.5% | 1.5% | 2.5% |
| 1Y | -48.7% | -11.3% | 14.4% |
Return vs Industry: 1BD underperformed the German Medical Equipment industry which returned -10.3% over the past year.
Return vs Market: 1BD underperformed the German Market which returned 14.9% over the past year.
Price Volatility
| 1BD volatility | |
|---|---|
| 1BD Average Weekly Movement | 21.1% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 1BD's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1BD's weekly volatility has decreased from 33% to 21% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 30 | Lone Carlbom | www.bio-works.com |
Bio-Works Technologies AB (publ), a biotechnology company, engages in the research, development, manufacture, and supply of agarose-based separation products to purify proteins, enzymes, antibodies, peptides, and other biomolecules primarily in Sweden. It offers activated and affinity resins; hydrophobic interaction chromatography resins; GoBio Mini columns; immobilized metal-ion affinity chromatography resins; ion exchange resins; desalting columns; RoboColumns and Optimo PRO 96 well screens; screening kits; and size exclusion chromatography resins. The company’s products are used in antibodies, his-tagged proteins, proteins, peptides, oligonucleotides, and viruses and vaccines applications.
Bio-Works Technologies AB (publ) Fundamentals Summary
| 1BD fundamental statistics | |
|---|---|
| Market cap | €9.28m |
| Earnings (TTM) | -€3.42m |
| Revenue (TTM) | €2.79m |
3.3x
P/S Ratio-2.7x
P/E RatioIs 1BD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1BD income statement (TTM) | |
|---|---|
| Revenue | SEK 30.49m |
| Cost of Revenue | SEK 5.45m |
| Gross Profit | SEK 25.04m |
| Other Expenses | SEK 62.39m |
| Earnings | -SEK 37.36m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.48 |
| Gross Margin | 82.13% |
| Net Profit Margin | -122.54% |
| Debt/Equity Ratio | 0% |
How did 1BD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 06:24 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bio-Works Technologies AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Klas Palin | Penser Access |